Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 30:17:961-975.
doi: 10.2147/DDDT.S403259. eCollection 2023.

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies

Yusuf Mushtaq #  1 , Maryam M Mushtaq #  2 , Zisis Gatzioufas  3 , Matteo Ripa  4 , Lorenzo Motta  5 , Georgios D Panos  1
Affiliations
Review

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies

Yusuf Mushtaq et al. Drug Des Devel Ther. .

Abstract

Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.

Keywords: Iluvien; diabetic macular oedema; intravitreal implant; posterior uveitis; retinal vein occlusion; steroid implant.

PubMed Disclaimer

Conflict of interest statement

Yusuf Mushtaq and Maryam M Mushtaq are co-first authors for this study. Lorenzo Motta and Georgios D Panos are co-correspondence authors for this study. The authors report no conflicts of interest in this work.

References

    1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875–912. doi: 10.1097/IAE.0b013e3181a94f01 - DOI - PubMed
    1. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787–794. doi: 10.1038/eye.2013.107 - DOI - PMC - PubMed
    1. Massa H, Nagar AM, Vergados A, Dadoukis P, Patra S, Panos GD. Intravitreal fluocinolone acetonide implant (ILUVIEN(R)) for diabetic macular oedema: a literature review. J Int Med Res. 2019;47(1):31–43. doi: 10.1177/0300060518816884 - DOI - PMC - PubMed
    1. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–587. doi: 10.1016/j.ophtha.2012.09.014 - DOI - PubMed
    1. Drugs.com. FDA approves iluvien; 2014. Available from: https://www.drugs.com/newdrugs/fda-approves-iluvien-diabetic-macular-ede.... Accessed March 23, 2023.

MeSH terms